NASDAQ · GEHC

GE HealthCare Technologies Inc.

$61.12 +$0.54 (+0.89%) 1D After hours

Key Metrics

$27.56B
Market cap
14.44×
P/E · TTM
$20.98B
Revenue · TTM
$1.91B
Net income
EPS · TTM $4.16
Dividend yield 0.2%
Free cash flow $1.52B
Beta · 1Y 0.98
EBITDA · TTM $2.88B
Gross margin 39.1%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 23
    A material event was filed (Form 8-K).

    8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)

    RECEIPT: SEC FORM 8-K, TIMESTAMPED
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Apr 29
    From its Feb 27 high, the share price fell 29%.

    Peak close $84.27 on Feb 27; trough close $59.49 on Apr 29. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -29%
  • Apr 29
    The stock moved -13.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Apr 29

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$27.56B
Enterprise value$35.07B
Shares outstanding454.9M
52-wk range$58.75 – $89.77
Avg volume · 20D3.5M
Net cash −$7.52B
Book value / share$23.24
IndustryX-Ray Apparatus & Tubes & Related Irradiation Apparatus
ExchangeNASDAQ
About GE HealthCare Technologies Inc.
IPO dateDec 15, 2022
Employees54000

GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E14.44
P/S1.31
P/FCF18.14
EV/EBITDA12.18
EV/Sales1.67
Graham №$46.64

Profitability

Gross 39.1%
Operating 12.3%
Net 9.1%
FCF 7.2%
ROE / ROIC 20.0% · 10.7%

Financial Health

Current ratio1.22
Quick ratio0.95
Debt / equity0.95
Debt / EBITDA 3.52
Net cash −$7.52B
Working capital$1.90B

Cash Flow · TTM

Operating CF $2.03B
Capex −$508.00M
Free cash flow $1.52B
Buybacks
Dividends paid $64.00M
Shareholder yield 0.2%

Piotroski F-Score

3 / 9
Weak fundamentals · 3 of 9 signals passing

Altman Z-Score

1.7
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

$46.64 vs $61.12
Trades 1.3× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings